Actinium Pharmaceuticals (ATNM) Q4 2024 earnings summary

Executive summary

• Actinium Pharmaceuticals focuses on developing targeted radiotherapies for advanced cancers, with lead programs in myeloid malignancies, solid tumors, and conditioning for cell and gene therapies.

• The company operates as a single segment, with no commercial revenue to date and a net loss of $38.2 million for 2024, an improvement from a $48.8 million loss in 2023.

• Key pipeline assets include Actimab-A (AML/MDS), Iomab-ACT (conditioning for cell/gene therapy), and ATNM-400 (prostate cancer), with multiple clinical trials ongoing or planned.

• Strategic priorities include establishing Actimab-A as a backbone therapy, expanding into solid tumors, and building in-house manufacturing capabilities.

Financial highlights

• No commercial revenue in 2024 or 2023; $0.1 million in grant revenue recognized in 2023.

• Research and development expenses decreased to $30.0 million in 2024 from $38.7 million in 2023, mainly due to lower CMC and consulting costs.

• General and administrative expenses fell to $12.1 million in 2024 from $13.3 million in 2023.

• Net loss for 2024 was $38.2 million, down from $48.8 million in 2023, driven by lower operating expenses and higher interest income.

• Cash and cash equivalents at year-end 2024 were $72.9 million, with $29.3 million raised from stock sales during the year.

Outlook and guidance

• Management expects existing resources to fund operations for more than 12 months from the report date.

• Additional funding will be required for future clinical trials, regulatory approvals, and potential commercialization.

• Multiple pivotal and proof-of-concept trials are planned for 2025, including a Phase 2/3 trial for Actimab-A + CLAG-M in r/r AML and new studies for Iomab-ACT in CAR-T and sickle cell disease.